 It is hypothesized that 1 the raltegravir regimen will have similar efficacy in terms of both viral suppression as well as increases in CD4 cell counts and 2 raltegravir will have significantly less impact on plasma lipids, lipoproteins and lipoproteins subtypes, compared with lopinavirritonavir. 